← Back to Patent Explorer
US5034514A Expired / Lapsed US ⏱️ 0.0 years remaining

Novel cross-linking agents

Assignee: Novartis Vaccines and Diagnostics Inc
•
Filing: 1988-10-12
•
Granted: 1991-07-23
•
Expires: 2008-10-12
📄 Original PDF 🌐 Google Patents 🔄 Sync Now

Abstract

Abstract Bifunctional chemicals useful for linking aldehyde containing moieties to moieties containing functionalities which are or can be reactive with sulfhydryl are claimed and have the formula: L--S--(CH.sub.2).sub.n1 --CONH--SPACER--NH--X wherein L is a leaving group selected from --H or --S--Ar, wherein Ar represents optionally substituted phenyl or pyridyl; n 1 =2-4; X is selected from: --CO--Y--CONHNH 2 , a hydrazide; ##STR1## a hydrazine; ##STR2## a hydrazine; --CO--Y--NH--CONHNH 2 , a semicarbazide; and --CO--Z--NH--CSNHNH 2 , a thiosemicarbazide; wherein Y is alkylene or oxaalkylene and Z is alkylene or a polypeptide residue briding the N-terminal amino group and C-terminal carboxy group thereof; the SPACER is oxaalkylene or oxaalkylene substituted with hydroxyl and specifically includes residues having formulas selected from a) --(CH 2 ) n2 --O--(CH 2 ) n2 --O--(CH 2 ) n2 -- wherein each n2 is independently 2-4 and b) ##STR3## wherein n3 is 2-6. Also claimed are hydrazides, semicarbazides, and thiosemicarbazides of ω-mercaptocarboxylic acids which lack SPACER diamine.

Inventors

  • 👤 Danute E. Nitecki
  • 👤 Margaret Moreland

Bibliographic Details

Application Number —
Jurisdiction US
Data Source google_patents
Last Synchronized 2026-11-07 20:59
CPC Classifications
G; G01; G01N; G01N33/00; G01N33/48; G01N33/50; G01N33/53; G01N33/543; G01N33/54353; C; C07; C07D; C07D213/00; C07D213/02; C07D213/04; C07D213/60; C07D213/62; C07D213/70; C07D213/71

Claims Analysis

Total Claims: 11
Claim 1
Independent Claim 11 words
An immunoglobulin-linker complex in which an immunoglobulin is conjugated to 1-{3-(2-pyridyldithio)propionamido}-12-{5-hydrazidoglutaramido}-4,9-dioxadodecane.
Claim 2
Dependent Claim 11 words
An immunoglobulin-linker complex in which an immunoglobulin is conjugated to 1-{3-(2-pyridyldithio)propionamido}-12-{5-hydrazidoglutaramido}-4,9-dioxadodecane.
Claim 3
Dependent Claim 62 words
An immunoglobulin-linker complex in which an immunoglobulin is conjugated to the compound selected from those of the formula L--S--(CH 2 ) n1 CONHNH 2 , L--S--(CH 2 ) n1 NHCONHNH 2 and L--S--(CH 2 ) n1 NHCSNHNH 2 wherein L is a leaving group selected from --H or --S--Ar, wherein Ar represents optionally substituted phenyl or pyridyl; and n 1 is 2-4.
Claim 4
Dependent Claim 62 words
An immunoglobulin-linker complex in which an immunoglobulin is conjugated to the compound selected from those of the formula L--S--(CH 2 ) n1 CONHNH 2 , L--S--(CH 2 ) n1 NHCONHNH 2 and L--S--(CH 2 ) n1 NHCSNHNH 2 wherein L is a leaving group selected from --H or --S--Ar, wherein Ar represents optionally substituted phenyl or pyridyl; and n 1 is 2-4.
Claim 5
Dependent Claim 16 words
The complex of claim 1, wherein said immunoglobulin is bound to 1-{3-(2-pyridyldithio)propionamido}-12-{5-hydrazidoglutaramido}-4,9-dioxadodecane through a disulfide linkage.
Claim 6
Dependent Claim 16 words
The complex of claim 2, wherein said immunoglobulin is bound to 1-{3-(2-pyridyldithio)propionamido}-12-{5-hydrazidoglutaramido}-4,9-dioxadodecane through a disulfide linkage.
Claim 7
Independent Claim 141 words
A method of making an immunoglobulin-linker complex, comprising the steps of: (a) providing a linker of the formula L--S--(CH 2 ) n1 --CONH--SPACER--NH--X wherein L is a leaving group selected from --H or --S--Ar, wherein Ar represents optionally substituted phenyl or pyridyl; n 1 =2-4; X is selected from --CO--Y--CONHNH 2 , a hydrazide; ##STR14## a hydrazine; ##STR15## a hydrazine; --CO--Y--NH--CONHNH 2 , a semicarbazide; and --CO--Z--NH--CSNHNH 2 , a thiosemicarbazide; wherein Y is alkylene or oxaalkylene and Z is alkylene, oxaalkylene, or a polypeptide residue bridging the N-terminal amino group and C-terminal carboxy group of said polypeptide; the SPACER is oxaalkylene or is oxaalkylene substituted with hydroxyl; and (b) oxidizing an immunoglobulin so as to provide an aldehyde residue on the immunoglobulin; (c) reacting the oxidized immunoglobulin with the --NHX moiety on the linker so that immunoglobulin linker is provided.
Claim 8
Independent Claim 141 words
A method of making an immunoglobulin-linker complex, comprising the steps of: (a) providing a linker of the formula L--S--(CH 2 ) n1 --CONH--SPACER--NH--X wherein L is a leaving group selected from --H or --S--Ar, wherein Ar represents optionally substituted phenyl or pyridyl; n 1 =2-4; X is selected from --CO--Y--CONHNH 2 , a hydrazide; ##STR14## a hydrazine; ##STR15## a hydrazine; --CO--Y--NH--CONHNH 2 , a semicarbazide; and --CO--Z--NH--CSNHNH 2 , a thiosemicarbazide; wherein Y is alkylene or oxaalkylene and Z is alkylene, oxaalkylene, or a polypeptide residue bridging the N-terminal amino group and C-terminal carboxy group of said polypeptide; the SPACER is oxaalkylene or is oxaalkylene substituted with hydroxyl; and (b) oxidizing an immunoglobulin so as to provide an aldehyde residue on the immunoglobulin; (c) reacting the oxidized immunoglobulin with the --NHX moiety on the linker so that immunoglobulin linker is provided.
Claim 9
Dependent Claim 29 words
The method of claim 5, further comprising reacting the immunoglobulin-linker complex with a sulfhydryl-containing moiety so that the complex is bound to the sulfhydryl-containing moiety through a disulfide bond.
Claim 10
Dependent Claim 36 words
A method of making an immunoglobulin-linker complex according to claim 5, wherein the oxaalkylene spacer is --(CH 2 ) n2 --O--(CH 2 ) n2 --O--(CH 2 ) n2 -- wherein each n 2 is independently 2-4.
Claim 11
Dependent Claim 25 words
A method of making an immunoglobulin-linker complex according to claim 5, wherein the oxaalkylene spacer substituted with hydroxyl is ##STR16## wherein n 3 is 2-6.

References Cited (Backward Citations)

US4867973A Cited
EP0294294A2 Cited

USPTO Annuity & Maintenance Windows

Annuity Stage Window Opens Payment Deadline Surcharge Period Until Estimated Fee Status
3.5 Years (Year 4) 1994-07-22 1995-01-21 1995-07-23 $2000.00 Window Closed / Lapsed
7.5 Years (Year 8) 1998-07-22 1999-01-21 1999-07-23 $3760.00 Window Closed / Lapsed
11.5 Years (Year 12) 2002-07-22 2003-01-21 2003-07-23 $7700.00 Window Closed / Lapsed

Assigned Categories & Tags

No categories assigned to this patent yet.

Assign Category Tag